Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

NCT00011414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Wilms' Tumor
Sarcoma
Adenaocortical Carcinoma
Refractory Cancer
Coldrhood Cancer

Interventions

DRUG: Tariquidar

Sponsor

National Cancer Institute (NCI)